A new study published by Canadian researchers in the British Medical Journal (BMJ) has found that patients who use the diabetes drug Actos are 63% more likely to develop bladder cancer. Researchers also found that this Actos bladder cancer risk increases the longer that patients are treated with the drug.
Executives with Takeda Pharmaceutical, the manufacturer of Actos, admitted that they had paid physicians to prescribe the drug to patients with pre-diabetes, a former GlaxoSmithKline executive and whistleblower testified recently in Massachusetts federal court. Peter P. Lawton, the former director of patent life-cycle maximization at GSK, said that Takeda engaged in a kickback scheme despite…
A new study published by the Journal of the American Medical Association (JAMA) has found that the diabetes drug Actos may increase the risk of pancreatic cancer and prostate cancer. Previous studies regarding the health effects of Actos have already linked the diabetes drug to an increased risk of bladder cancer.
Takeda Pharmaceuticals has agreed to pay $2.4 billion to settle thousands of lawsuits filed by patients who developed bladder cancer after taking the diabetes drug Actos. The Actos settlement agreement will one of the largest pharmaceutical liability settlements ever reached.
Takeda Pharmaceutical has reportedly offered $2.2 billion to settle thousands of lawsuits filed against the drug company involving diabetes drug Actos and bladder cancer diagnosis in patients who used this medication. The settlement proposal, first reported by Bloomberg News, would be the first in the three-year Actos litigation history, which has involved more than 8,000 bladder…
A proposed class action regarding the drug Actos will be part of a larger multidistrict litigation (MDL) taking place in Louisiana but will be tried separately. U.S. District Judge Rebecca Doherty issued the order for a separate trial last month.
Terrence Allen is one of thousands of people who have filed claims against the drug companies behind the diabetes drug Actos. Mr. Allen has bladder cancer and says Actos is to blame. Allen sued Takeda Pharmaceutical Co. and Eli Lilly & Co. alleging that company executives ignored or downplayed concerns about the drug’s cancer-causing potential…
Takeda Pharmaceutical Co. and Eli Lilly & Co. have been ordered to pay a combined $9 billion over charges that the two companies hid evidence of a link between Actos and bladder cancer, a Louisiana jury has ruled. The award was the seventh largest ever handed down for a trial in the U.S., according to…
Takeda Pharmaceuticals is facing 14 lawsuits filed against the company by patients in Indiana who were diagnosed with bladder cancer after taking the diabetes drug Actos. More than 3,000 Actos bladder cancer lawsuits have been filed against Takeda on behalf of former patients or their families.
A California state court jury on April 26, 2013 awarded a $6.5 million verdict to plaintiff Jack Cooper in the first Actos bladder cancer case to go to trial. Cooper’s case is one of more than 3000 similar cases pending against Takeda Pharmaceuticals alleging that their popular diabetes drug causes bladder cancer and other serious…
Lawyers in the first Actos lawsuit to go to trial stated in their closing arguments last week that Takeda Pharmaceuticals hid the drug’s risk of causing bladder cancer from patients in order to protect billions of dollars in sales. More than 3,000 Actos users have filed lawsuits against Takeda alleging that they developed bladder cancer…
Lawyers in the first Actos lawsuit to go to trial say that the manufacturer of the drug failed to warn doctors about the bladder cancer risk of the diabetes medication. Attorneys representing former Actos user Jack Cooper say that Takeda Pharmaceuticals failed to alert Cooper’s doctor that Actos could increase his patients’ risk of bladder…